Ablynx Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Ghent Belgium (2001)
Status: Acquired by Sanofi-Aventis (2018)

Organization Overview

First Clinical Trial
2008
NCT00916110
First Marketed Drug
2019
caplacizumab (cablivi)
First NDA Approval
2019
caplacizumab (cablivi)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ablynx | Ablynx NV | ABLYNX NV